Sunil Verma, MD | Authors

June 06, 2017

Sunil Verma, MD, department head, Clinical Department of Oncology, Calgary Zone, medical director, Tom Baker Cancer Centre, discusses updated results of the phase III MONALEESA-2 trial of first-line ribociclib plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer during the 2017 ASCO Annual Meeting.

March 30, 2016

Sunil Verma, MD, Medical Director, Tom Baker Cancer Centre, Professor and Department Head, Oncology, Cumming School of Medicine, University of Calgary, discusses the future of immunotherapies and anti-HER2 drugs in the treatment paradigm for HER2-positive breast cancer.

March 25, 2016

Verma says one of the major new understandings of the disease is that the HER2 receptor needs to be suppressed at all times within the treatment paradigm of the malignancy.